Show simple item record

dc.contributor.authorBozić Stanojević, Milica
dc.contributor.authorBetriu i Bars, M. Àngels
dc.contributor.authorBermúdez López, Marcelino
dc.contributor.authorOrtiz, Alberto
dc.contributor.authorFernández i Giráldez, Elvira
dc.contributor.authorValdivielso Revilla, José Manuel
dc.date.accessioned2018-04-25T08:19:53Z
dc.date.available2018-04-25T08:19:53Z
dc.date.issued2018
dc.identifier.issn1555-9041
dc.identifier.urihttp://hdl.handle.net/10459.1/63140
dc.description.abstractBackground and objectives: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. Design, setting, participants, & measurements: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. Results: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4–5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). Conclusions: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.
dc.description.sponsorshipThis work was supported by the intramural program of the IRBLleida, the Instituto de Salud Carlos III (RETIC RD16/0009/0011, FIS PI16/01354) and FEDER funds. The authors would like to thank the NEFRONA team (Eva Castro, Virtudes María, Teresa Molí, Teresa Vidal, Meritxell Soria) and the Biobank of RedInRen for their invaluable support. The NEFRONA study investigator group is listed in the supplementary material.
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherAmerican Society of Nephrology
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.2215/CJN.07980717
dc.relation.ispartofClinical Journal of The American Society of Nephrology, 2018, vol. 13, núm. 4, p. 577-584
dc.rights(c) American Society of Nephrology, 2018
dc.subjectAtherosclerosis
dc.subjectCardiovascular disease
dc.subjectPlaque, Atherosclerotic
dc.titleAssociation of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
dc.title.alternativeSubclinical Atheromatosis progression and FGF-2 in CKD
dc.typeinfo:eu-repo/semantics/article
dc.date.updated2018-04-25T08:19:54Z
dc.identifier.idgrec026813
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.identifier.doihttps://doi.org/10.2215/CJN.07980717


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record